

February 15, 2019

To whom it may concern:

|                          |  |
|--------------------------|--|
| Company Name             | TOHO HOLDINGS CO., LTD.  |
| Corporate Representative | Norio Hamada, Chairman of the Board and Representative Director, Chief Executive Officer (CEO)<br>(First Section of Tokyo Stock Exchange Securities Code:8129) |
| Contact:                 | Makoto Kawamura, Director and General Manager, Public and Investor Relations Department<br>(TEL: 81-3-6838-2803)   |

**Notice Regarding Marketing Approvals for  
1 Ingredient / 4 Products of Generic Drugs for KYOSOMIRAI PHARMA**

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Chairman of the Board and Representative Director, Chief Executive Officer (CEO): Norio Hamada) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has received approvals for marketing of 1 ingredient / 4 products of generic drugs today on February 15, 2019 as below.

Products list approved for marketing

| Class   | Product Name                            | Original Brand Name     |
|---|---|-------------------------|
| Selective $\alpha$ 1A blocker<br>Improving agent for urination<br>disorders associated with benign<br>prostatic hyperplasia | Silodosin Tablets<br>2mg / 4mg “KMP”    | URIEF Tab. 2mg / 4mg    |
|   | Silodosin OD Tablets<br>2mg / 4mg “KMP” | URIEF OD Tab. 2mg / 4mg |